Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sung Hoon Sim

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
British Journal of Cancer|November 7, 2019
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)Sung Hoon Sim, In Hae Park, Kyung Hae Jung, et al.
Scientific Reports|June 19, 2023
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancerKyoungmin Lee, Jongwon Lee, Jungmin Choi, et al.
JAMA Oncology|July 7, 2022
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical TrialHee Kyung Ahn, Sung Hoon Sim, Koung Jin Suh, et al.
Plos One|August 4, 2017
CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancerSung Hoon Sim, Chang-Dae Bae, Youngmi Kwon, et al.
Journal of Breast Cancer|January 30, 2026
Prospective Single-Arm Study of Endocrine Therapies With Ovarian Function Suppression in Premenopausal Node-Positive Early Breast Cancer Patients With Low Genomic Risk (INTERSTELLAR Trial, KBCSG-25)Sung Gwe Ahn, Sung Hoon Sim, Taewoo Kang, et al.
Breast (Edinburgh, Scotland)|August 27, 2022
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, et al.
Cancer Research and Treatment|March 15, 2021
Guidelines for Cancer Care during the COVID-19 Pandemic in South KoreaJii Bum Lee, Minkyu Jung, June Hyuk Kim, et al.
Cancer Research and Treatment|March 28, 2022
Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)Jieun Lee, Keun Seok Lee, Sung Hoon Sim, et al.
Breast Cancer (Tokyo, Japan)|June 24, 2026
Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trialTakashi Yamanaka, Joohyuk Sohn, Kazuki Sudo, et al.
Therapeutic Advances in Medical Oncology|January 30, 2024
A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)Sun Kyung Baek, Jae-Ho Jeong, KyungHae Jung, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
British Journal of Cancer|November 7, 2019
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)Sung Hoon Sim, In Hae Park, Kyung Hae Jung, et al.
Scientific Reports|June 19, 2023
Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancerKyoungmin Lee, Jongwon Lee, Jungmin Choi, et al.
JAMA Oncology|July 7, 2022
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical TrialHee Kyung Ahn, Sung Hoon Sim, Koung Jin Suh, et al.
Plos One|August 4, 2017
CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancerSung Hoon Sim, Chang-Dae Bae, Youngmi Kwon, et al.
Journal of Breast Cancer|January 30, 2026
Prospective Single-Arm Study of Endocrine Therapies With Ovarian Function Suppression in Premenopausal Node-Positive Early Breast Cancer Patients With Low Genomic Risk (INTERSTELLAR Trial, KBCSG-25)Sung Gwe Ahn, Sung Hoon Sim, Taewoo Kang, et al.
Breast (Edinburgh, Scotland)|August 27, 2022
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B)Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, et al.
Cancer Research and Treatment|March 15, 2021
Guidelines for Cancer Care during the COVID-19 Pandemic in South KoreaJii Bum Lee, Minkyu Jung, June Hyuk Kim, et al.
Cancer Research and Treatment|March 28, 2022
Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)Jieun Lee, Keun Seok Lee, Sung Hoon Sim, et al.
Breast Cancer (Tokyo, Japan)|June 24, 2026
Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trialTakashi Yamanaka, Joohyuk Sohn, Kazuki Sudo, et al.
Therapeutic Advances in Medical Oncology|January 30, 2024
A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)Sun Kyung Baek, Jae-Ho Jeong, KyungHae Jung, et al.
Pageof 8